AUTHORS
Shubang Xie, N/A, Haiwen Huang, PhD2, Longfei He I, MS3, Wanying Chen4, Ming Jin5, Tao You, MD6, Jin Zhou, MD7, Depei Wu, MD, PhD8
AFFILIATIONS
1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
2 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
3 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
4 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
5 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
6 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
7 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
8 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
ABSTRACT
Background
The therapeutic landscape of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has evolved rapidly with the introduction of novel therapies, particularly bispecific antibodies (BsABs). However, real-world evidence regarding whether improved accessibility to these agents translates into better clinical outcomes remains limited.
Aims
To evaluate the impact of increased accessibility to novel therapies following national reimbursement of BsABs in China on treatment patterns, clinical efficacy, survival outcomes, and safety among patients with R/R DLBCL receiving third-line or later (3L+) therapy.
Methods
We conducted a retrospective single-center cohort study including 84 consecutive patients with R/R DLBCL who initiated 3L+ therapy between January 2020 and December 2024. Patients were classified into the pre-BsAB era (2020–2023, n=37) and the BsAB era (2024, n=47) according to the calendar period in which third-line therapy was initiated. Baseline characteristics, treatment patterns, overall response rate (ORR), complete response (CR), event-free survival (EFS), overall survival (OS), and Grade ≥3 adverse events (AEs) were compared between groups. Survival outcomes were evaluated using the Kaplan–Meier method with log-rank testing, and Cox proportional hazards regression was performed to estimate hazard ratios (HRs).
Results
Baseline demographic and disease characteristics were generally comparable between groups (all P>0.05). Following national reimbursement of BsABs in 2024, treatment patterns changed substantially, with BsAB utilization increasing from 13.5% in the pre-BsAB era to 48.9% in the BsAB era (P=0.0009). Patients treated during the BsAB era achieved a significantly higher CR rate than those treated in the pre-BsAB era (31.9% vs. 10.8%; P=0.034), while ORR showed a numerical improvement. Kaplan–Meier analysis demonstrated significantly improved OS in the BsAB era (median OS, 24.0 vs. 19.0 months; log-rank P=0.0227). In multivariable Cox regression analysis, treatment during the BsAB era remained independently associated with superior OS (adjusted HR 0.29, 95% CI 0.12–0.67; P=0.004). EFS was also significantly prolonged (12.0 vs. 5.0 months; log-rank P=0.0058; HR 0.52, 95% CI 0.32–0.86; P=0.011). The incidence of Grade ≥3 AEs was comparable between groups (60.0% vs. 57.1%; P=0.823).
Conclusions
In this single-center real-world cohort, increased accessibility to novel therapies following national reimbursement of BsABs was associated with substantial changes in treatment patterns, significantly higher complete response rates, and improved survival outcomes without increasing severe toxicity in patients receiving third-line or later therapy for R/R DLBCL. These findings provide real-world evidence supporting the integration of innovative immunotherapies into later-line treatment strategies and warrant validation in larger multicenter cohorts.
DISCLOSURES
Haiwen Huang, PhD: No relevant conflicts of interest to declare.